Skip to main content

Table 4 Comparison masitinib safety profile in nononcology phase 2 studies

From: Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

  Phase 2 nononcology studiesa Alzheimer study
  Controlled Masitinib
( n = 79)
Placebo
( n = 25)
Noncontrolled Masitinib
( n = 137)
Masitinib ( n = 26) Placebo
( n = 8)
At least one AE 73 (92%) 19 (76%) 122 (89%) 17 (65%) 3 (38%)
Serious AEs 22 (27%) 3 (12%) 35 (26%) 6 (23%) 1 (13%)
AE (withdrawal)b 25 (32%) 2 (8%) 44 (32%) 7 (27%) 0
Severe AE 35 (44%) 5 (20%) 49 (36%) 4 (15%) 1 (13%)
Dose reductionc 8 (10%) 0 (0%) 11 (8%) 4 (15%) 0
  1. AE, adverse event. aExcluding current Alzheimer study. bAE leading to patient withdrawal from study. cAE leading to dose reduction.